^
Association details:
| Biomarker: | NPM1 mutation |
|---|---|
| Cancer: | Chronic Myelomonocytic Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2189 Activity of Venetoclax-Based Therapy in CMML and CMML with Blast Transformation
Published date:
11/04/2020
Excerpt:
We retrospectively reviewed pts with CMML, both with and without BT, treated with VEN-based therapy…NPM1 mutations predict for CR and RUNX1 mutations are associated with a trend to higher ORR.
